Globally, 595 million people live with osteoarthritis (OA). This number is projected to reach 1.04 billion by 2050.*
Our mission is to treat osteoarthritis and get people moving without pain.
About
Sparta Biomedical is creating the first-of-its-kind chemically engineered cartilage platform, Hyalos. The degeneration of cartilage between joints can cause significant personal, economic, and societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time. We are developing cartilage-like implants for the all of the important joints in the body.
solving a massive problem that affects the world’s population
address cartilage degeneration
intersection of chemistry, mechanical engineering, biology
Hyalos is a Multi-Indication Platform
Shoulder
Thumb
Partial knee
Ormi™
Patella
Elbow
Hip
Trochlea
Ankle
Toe
Hyalos Spotlight
The first MTP hemiarthroplasty device combining Hyalos - a cartilage-mimicking hydrogel - with a proprietary titanium fixation technology for exceptional stability and bone integration. Unlike traditional round implants, Karthyx replicates the unique biomechanics of the great toe, providing natural motion and long-lasting joint function. With round-shaped implants, excessive cutting of the bone can lead to bad integration and loosening of the implant. With Karthyx, only cartilage is removed and the cortical bone layer is smoothed. Available in multiple sizes, the implant is designed to restore natural motion and long-lasting relief.
Big Toe / Karthyx
Karthyx Has No Equal
Karthyx
Durable Cartilage-Like Contact Surface
Joint Conforming Head
Osseointegrative Stem Surface
Bone Preserving
No Opposing Surface Wear
Strong Fixation
Alternatives
Non Durable Cartilage-Mimicking Surface
Non-Conforming Head
Non-Porous Stem
Bone Preserving
No Opposing Surface Wear
Strong Fixation
Leadership Team
We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas, and are driven by a common purpose; we seek to advance the standard of care for osteoarthritis and get people moving again without pain.
Travis Entrop
Senior R&D Engineer
Contact Us
* (GBD 2021 Osteoarthritis Collaborators (2023). Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. Rheumatology, 5(9), e508–e522. GBD 2021 Osteoarthritis Study